Biotech Values

[genisi]

Just to make something clear: the 7,817 patients with STEMI mentioned in the quote are the major pre-specified subgroup from the ATLAS ACS 2-TIMI 51 study, and similar to the primary analysis of that study (#msg-68953169), Xarelto reduced recurrent CV events in this sub group, but there were also stat-sig more bleeding (major but not fetal), with Xarelto than the placebo.